**TO THE EDITOR:** The co-expression of CD3 in B-cell lineage lymphomas or the aberrant co-expression of CD20 in T-cell lineage lymphomas has been rarely reported. We describe a 72-year-old female, who presented with systemic lymphadenopathy and a 2 cm-sized gastric mass. Biopsies of the lymph node and the gastric mass showed diffuse sheets of large, atypical lymphoid cells. The tumor cells were positive for B-cell antigens such as CD20 and CD79a as well as for the T-cell antigen CD3 and cytotoxic molecule TIA-1. *In situ* hybridization for Epstein-Barr virus-encoded RNA (EBER) showed positive signals in the nuclei of the majority of tumor cells. Molecular studies revealed rearrangements of the immunoglobulin heavy chain (*IgH*) region and the T-cell receptor (*TCR*)-*γ* genes, but not the *TCR-β* genes. The patient was treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in near-total remission. This case illustrates the difficulty of lineage determination of non-Hodgkin lymphomas with only pan-B- and pan-T-cell markers. Unlike the previously reported cases, the present case showed molecular markers of both the B- and T-cell lineages, which further complicates the interpretation. The association of CD3-positive diffuse large B-cell lymphoma (DLBCL) with the Epstein-Barr virus (EBV) warrants further study.

Lymphoma diagnosis is based on histomorphology, immunophenotyping, flow cytometry, and molecular studies. Lymphomas are broadly classified as being of the B-cell and T-cell lineages, using immunohistochemistry and/or flow cytometry. Among the markers to determine B- and T-cell lineages, CD20 and CD3 are the most commonly used. T-cell lymphomas with aberrant expression of the B-cell marker CD20 or B-cell lymphomas with aberrant expression of T-cell associated antigens such as CD5, CD43, CD7, CD2, CD4, and CD8 have been reported \[[@B1]-[@B5]\]. However, cases of B-cell lymphoma with CD3 co-expression are extremely rare \[[@B6], [@B7]\]. Herein, we report a case of diffuse large B-cell lymphoma (DLBCL) in an elderly patient, with an aberrant co-expression of the T-cell associated antigen CD3 and cytotoxic molecule TIA-1, an infection with EBV, and a dual rearrangement of the immunoglobulin heavy chain (*IgH*) and T-cell receptor (*TCR*)-*γ* genes, but not the *TCR-β* gene.

CASE
====

A 72-year-old, HIV-negative Korean female presented with easy fatigue and epigastric discomfort, which had been gradually worsening over a period of 4 months, and weight loss of 3 kg over a period of 1 month. She had a history of stroke, hypertension, and osteoporosis with spinal fractures. Laboratory tests on admission revealed an elevated serum lactate dehydrogenase level (489 IU/L; reference range, 120-250 IU/L) with a slightly decreased serum hemoglobin level (10.2 g/dL; reference range, 12-16 g/dL). Computed tomography (CT) scans of the neck, chest, and abdomen showed multiple lymph node enlargements in the left supraclavicular area and the retroperitoneum, with a 7.5 cm cystic lesion in the left perirenal space. A 2 cm-sized gastric mass with central ulceration was noted during esophagogastroduodenoscopy (EGD). A biopsy of the left supraclavicular lymph node showed a partial effacement of the nodal architecture with diffuse infiltration by large atypical tumor cells separated by collagenous septae ([Fig. 1](#F1){ref-type="fig"}). There were also multiple foci of geographic necrosis. These cells had pleomorphic nuclei, vesicular chromatin, prominent macronucleoli, and numerous mitotic figures, with many bizarre Reed-Sternberg (RS)-like multinucleated cells. Admixed with the tumor cells were small numbers of mature small lymphocytes and macrophages. A gastric biopsy also revealed similar findings. Immunohistochemistry showed that the tumor cells were positive for CD20, CD79a, CD3, MUM-1, BCL-2, TIA-1, CD43, OCT-2, and BOB-1, weakly positive for PAX-5, but negative for CD2, CD5, CD4, CD8, granzyme B, TCR-β F1, TCR-γ receptor, BCL-6, CD10, ALK-1, CD30, CD15, myeloperoxidase, and CD163. In the background, there were only a few scattered T cells, some of which were positive for TIA-1. *In situ* hybridization for Epstein-Barr virus-encoded RNA (EBER) showed positive nuclear signals in almost all tumor cells. A quantitative real-time PCR for Epstein-Barr virus (EBV) in the patient\'s serum showed that the EBV load was high (131,000 copies/mL). Clonality studies using multiplex PCR with BIOMED-2 primers (InVivoScribe Technologies, San Diego, CA, USA) revealed a dual rearrangement of *IgH* genes and *TCR-γ* genes ([Fig. 2](#F2){ref-type="fig"}), whereas a *TCR-β* gene rearrangement study failed to identify a monoclonal T-cell population. Based on the expression of almost all B-cell-associated antigens and the monoclonal rearrangement of *IgH* genes, the patient was diagnosed with EBV-positive DLBCL of the elderly with an aberrant expression of CD3 and TIA-1. Tumor cells were also noted in bone marrow biopsy and clot sections, assigning her to the Ann Arbor stage 4B. She received 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), which resulted in almost complete remission. A follow-up positron emission tomography (PET) scan 8 months after the diagnosis revealed the disappearance of hypermetabolic lesions from the left supraclavicular area, retroperitoneum, and stomach. However, a cystic lesion with calcifications in the perirenal space, which seemed to be non-neoplastic (e.g., a postinflammatory calcification, a pseudocyst, or an old hematoma), was persistently observed on 3 follow-up CT scans after chemotherapy (R-CHOP) with salvage radiotherapy (3,060 cGy/20 fx, 5 weeks) for the perirenal lesion.

DISCUSSION
==========

Non-Hodgkin lymphomas (NHL) are assigned to B-cell and T-cell lineages based on immunoprofiling, flow cytometry, and molecular studies. We describe a case of a large cell lymphoma with the hybrid expression of both B- and T-cell markers, monoclonal gene arrangement of both lineages, and EBV infection. This case illustrates the difficulty of determining of the lineage of non-Hodgkin lymphoma using only pan-B-cell or pan-T-cell markers.

Based on the histopathologic features, the age of the patient, and the expression of EBER, CD20, MUM-1, BCL-2, OCT-2, and BOB-1, a diagnosis of EBV-positive DLBCL of the elderly was favored, despite the cytoplasmic expression of CD3 and TIA-1. Because classical Hodgkin lymphoma (cHL) in older patients is also often associated with EBV infection, it should be included as a major differential diagnosis. In EBV-positive DLBCL of the elderly, tumor cells are often positive for CD30; consequently, CD30 expression is not helpful for differential diagnosis. A strong, homogenous expression of CD20 in more than 50% of the RS-like cells in combination with the expression of B-cell specific transcription factors such as OCT-2 and BOB-1 support a diagnosis of EBV-positive DLBCL. In addition, the finding that over 30% of the cytotoxic T-cells in the background infiltrate expressed TIA-1 favors EBV-positive DLBCL over EBV-positive cHL.

However, in the present case, the expression of CD3, the most specific surface antigen for mature T-lymphocytes in pleomorphic large cells, led to a diagnostic dilemma. Although several reports describe aberrant expression of the B-cell marker CD20 in T-cell NHL or aberrant expression of T-cell-associated antigens such as CD2, CD4, CD7, and/or CD8 in B-cell NHL (B-NHL) \[[@B1]-[@B5]\], there are only 3 reports (9 cases in all) of CD3-positive B-NHL \[[@B6], [@B7]\]. Several mechanisms have been proposed to explain the aberrant expression of T-cell antigens by neoplastic B cells: 1) neoplastic transformation leading to the consequent derepression of genetic material, 2) neoplastic transformation of stem/progenitor cells, and 3) neoplastic expansion of a subpopulation of B cells which normally express T-cell antigens \[[@B6]\]. Another hypothesis is associated with the transcription factor encoded by the *paired box 5* (*PAX-5*) gene \[[@B8]\]. *PAX-5* activates B-cell-specific genes leading to B-cell lineage commitment and represses B-cell lineage-inappropriate genes, such as the T-cell specification gene, *NOTCH1*. It also encodes the transcription factor BSAP, which is critical for early B-cell lymphopoiesis and for maintaining B-lymphocyte differentiation. Immunoperoxidase staining for PAX-5 showed BSAP expression, which is highly indicative of B-cell differentiation and a B-cell lymphoma. Cobaleda et al. demonstrated that, in the absence of PAX-5, mature B lymphocytes can be transformed into functional T-lymphocytes \[[@B9]\]. In other words, B cells showing damaged and/or deregulated PAX-5 activity may occur in biphenotypic lymphomas that express PAX-5. This supports the hybrid features of this case, which showed weak immunopositivity for PAX-5. In addition, co-expression of CD3 most likely requires that repressed B-cell lineage-inappropriate genes such as *NOTCH1* are activated \[[@B10]\].

Another dilemma encountered in the diagnosis of this case resulted from the observation that there were dual rearrangements in both cell lineages. Dual or aberrant rearrangements, in which B- or T-cell phenotype lymphomas show monoclonality of both cell lineages (so-called \"lineage infidelity\") have been reported \[[@B11]-[@B15]\]. The percentage of aberrant rearrangement is between 5% and 29% for both B- and T-cell lymphomas. Garcia et al. reported that 21% of B-NHL cases showed a monoclonal pattern in one of the *TCR* genes (*TCR-β*, 16%; *TCR-γ*, 7%), and 16% of T-NHL cases showed an *IgH* gene monoclonal pattern. Their study demonstrated that a *TCR-γ* gene analysis has higher sensitivity than a *TCR-β* gene analysis. Födinger et al. reported that 13% of B-cell lymphomas exhibited a clonal *TCR-γ* rearrangement and 29% of T-cell lymphomas showed a monoclonality of the *IgH* gene rearrangement.

Though the tumor in the present study showed a hybrid phenotype, the patient received R-CHOP therapy, with almost complete remission seen on a follow-up PET scan. The patient\'s response to R-CHOP treatment also supports the initial diagnosis of EBV-positive DLBCL with an aberrant expression of CD3 and TIA-1.

To the best of our knowledge, this is the first case of EBV-positive DLBCL with an aberrant expression of CD3, TIA, and dual monoclonal rearrangement of the *IgH* and *TCR-γ* genes. EBV infection may contribute to the transformation of B cells, with ensuing PAX-5 deregulation. This would result in a hybrid immunoreactivity pattern, with positivity for CD20, CD3, and TIA-1 and lineage infidelity. This case serves as a cautionary note of the diagnostic pitfalls involved in the lineage determination of NHL using only pan-B- and pan-T-cell markers. More extensive immunoprofiles and molecular studies are needed for an integrated interpretation and accurate diagnosis. Additionally, the association between the co-expression of CD20, CD3, and TIA-1 and EBV infection warrant further study.
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![**(A)** Pleomorphic large tumor cells with prominent nucleoli, vesicular chromatin, and scanty cytoplasm are admixed with small numbers of mature lymphocytes. **(B)** A positive *in situ* hybridization for EBER in tumor cell nuclei is seen. **(C-E)** The neoplastic cells are diffusely and strongly positive for the T-cell marker CD3 **(C)**, the B-cell marker CD20 **(D)**, and the cytotoxic molecule TIA-1 **(E)** (**A-E,** ×400).](br-48-156-g001){#F1}

![This tumor demonstrates dual rearrangement (red arrows) of *IgH* genes **(A)** and *TCR-γ* genes **(B)** by multiplex PCR.](br-48-156-g002){#F2}
